Exclusive Summary

• Bromfenac sodium eye drops' original patents have expired in major markets, facilitating market entry for generics, and the preservative-free formulation offers a competitive differentiation.
• The global cataract surgery volume is steadily increasing, creating a vast and essential demand for postoperative inflammation and pain management.
• As an NSAID, Bromfenac sodium is a first-line treatment recommended by clinical guidelines for post-cataract surgery, ensuring clear clinical demand.
• Chinese manufacturers can leverage cost efficiencies to provide a more competitively priced product compared to originator drugs and existing generics.
• The preservative-free 0.4% formulation meets specific patient needs, improving adherence and safety, thereby gaining broader market acceptance.